| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/100-1/200 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human LGALS3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与LGALS3(半乳糖凝集素-3)抗体相关的文献摘要信息，供参考：
---
1. **文献名称**：*Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy*
**作者**：Raz A, et al.
**摘要内容**：该综述探讨了半乳糖凝集素-3(LGALS3)在炎症、癌症和纤维化中的病理作用，并总结了针对LGALS3的单克隆抗体在疾病诊断和治疗中的应用潜力，包括抗体阻断实验对肿瘤转移的抑制作用。
---
2. **文献名称**：*The role of galectin-3 in heart failure and cardiovascular disease*
**作者**：de Boer RA, et al.
**摘要内容**：研究分析了LGALS3在心肌纤维化和心力衰竭中的作用，通过特异性抗体检测发现血浆LGALS3水平与心血管疾病预后相关，提示其可作为生物标志物和潜在治疗靶点。
---
3. **文献名称**：*Antibody-mediated inhibition of galectin-3 blocks tumor progression in preclinical models*
**作者**：Glinsky VV, et al.
**摘要内容**：该研究开发了一种抗LGALS3的单克隆抗体(M3/38)，在动物模型中证明其能抑制肿瘤细胞粘附和血管生成，显著降低转移性癌症的进展，揭示了抗体靶向治疗的可行性。
---
如需具体文献链接或更详细内容，可进一步提供PMID或DOI编号。
The LGALS3 antibody targets galectin-3. a protein encoded by the LGALS3 gene, which belongs to the galectin family of β-galactoside-binding lectins. Galectin-3 is a multifunctional protein involved in cell adhesion, proliferation, apoptosis, immune regulation, and intracellular signaling. Structurally, it contains a carbohydrate-recognition domain (CRD) that mediates interactions with glycoproteins and glycolipids, enabling its role in modulating cell-cell and cell-matrix interactions.
Galectin-3 is implicated in various pathological processes, including cancer progression, fibrosis, inflammation, and cardiovascular diseases. In cancer, it promotes tumor growth, angiogenesis, and metastasis, making it a potential biomarker and therapeutic target. LGALS3 antibodies are widely used in research to detect galectin-3 expression in tissues or biological fluids via techniques like immunohistochemistry, Western blotting, or ELISA. They also serve as tools to study galectin-3's functional roles in disease models, such as blocking its activity to assess therapeutic effects.
Clinically, galectin-3 levels are measured using LGALS3 antibodies in diagnostic assays for heart failure stratification and fibrosis-related disorders. Therapeutic antibodies or inhibitors targeting galectin-3 are under investigation for conditions like idiopathic pulmonary fibrosis and certain cancers. However, challenges remain in understanding its context-dependent roles, as galectin-3 can exhibit both pro- and anti-inflammatory effects depending on the disease microenvironment. Ongoing research aims to refine LGALS3 antibody applications for precision diagnostics and targeted therapies.
×
